RareResearch.AI
← Back to atlas

c.229_230del

FrameshiftF1Pathogenic/Likely pathogenicCytoplasmic · predicted
Frameshift variant · frameshift point at position 77 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

F1Frameshift, NMD-targeted — null allele

Wild-type vs Translated Product

Wild-type · full length
Full wild-type wolframin · 890 aa — frameshift point at residue 77
Fullscreen ↗
Translated product
Native sequence to residue 76; everything highlighted is non-native (scrambled) or lost
Fullscreen ↗

Left: full-length wild-type wolframin (890 aa) with the frameshift point at residue 77 marked. Right: the same model with the non-native (scrambled) and lost region (residues 77–890) marked — what the frameshift transcript fails to produce as native protein.

Structural / NMD Prediction

Variant type
Frameshift
NMD status
NMD-targeted
high confidence
Schema
F1
Frameshift, NMD-targeted — null allele
Native protein retained
8.5%
PTC at aa 88

Stop codon at position 88 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Therapeutic Implication · F1

The frameshift creates a premature termination codon well upstream of the last exon-exon junction; the 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No frameshifted protein is produced — functionally a null allele. Therapeutic options: (a) translational readthrough drugs (Ataluren/PTC124, aminoglycosides) — notably LESS effective for frameshifts than for nonsense variants, because reading through the PTC still yields out-of-frame protein; (b) gene therapy via allele replacement is the higher-yield path.

Protein Domains

Retained (aa 1–76)
Lost / non-native (downstream)
  • Transmembrane helix 1311331
  • Cytoplasmic loop 1332340
  • Transmembrane helix 2341361
  • Lumenal loop 1362370
  • Transmembrane helix 3371391
  • Cytoplasmic loop 2392400
  • Transmembrane helix 4401421
  • Lumenal loop 2422431
  • Transmembrane helix 5432452
  • Cytoplasmic loop 3453461
  • Transmembrane helix 6462482
  • Lumenal loop 3483496
  • Transmembrane helix 7497517
  • Cytoplasmic loop 4518532
  • Transmembrane helix 8533553
  • Lumenal loop 4554573
  • Transmembrane helix 9574594
  • Cytoplasmic loop 5 / pre-lumenal595599
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)600890

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review status
Associated conditions
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.229_230del
ClinVar variantc.229_230del
ClinVar accession
Last evaluated

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Classified forno review status

ClinVar classifies this variant as Pathogenic/Likely pathogenic, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: no ClinVar review status recorded. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
Absent from gnomAD v4
Homozygotes
Not available

No population breakdown — the variant is absent from gnomAD v4, so no ancestry group has an observed frequency.

No homozygotes — the variant is absent from gnomAD v4 altogether.

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the c.229_230del card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this F1 frameshift variant and its domain context.

Full Variant Card

c.229_230del — WFS1 Molecular Atlas Card

Variant type: Frameshift Frameshift point: residue 77 Predicted premature stop (PTC): residue 88 Domain context (where the frame breaks): N-terminal cytoplasmic (intrinsically disordered)


Schema category: F1 — Frameshift, NMD-targeted — null allele

The frameshift creates a premature termination codon well upstream of the last exon-exon junction; the 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No frameshifted protein is produced — functionally a null allele. Therapeutic options: (a) translational readthrough drugs (Ataluren/PTC124, aminoglycosides) — notably LESS effective for frameshifts than for nonsense variants, because reading through the PTC still yields out-of-frame protein; (b) gene therapy via allele replacement is the higher-yield path.


Premature-stop prediction

  • Frameshift point: aa 77
  • Predicted PTC: aa 88 (11 codons downstream of the frame break)
  • Method: deterministic translation of edited NM_006005.3 CDS (frameshift position = first changed residue, HGVS convention)
  • Confidence: high

NMD prediction

  • Status: NMD-targeted
  • Confidence: high
  • Reasoning: Stop codon at position 88 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Protein consequence

  • Native (wild-type) sequence retained: aa 1 – 76 (8.5% of full-length protein)
  • Non-native scrambled stretch: aa 77 – 87 (11 residues of out-of-frame sequence)
  • Lost beyond the PTC: aa 88 – 890 (803 residues)

Native domains retained (upstream of the frameshift)

(no domains fully retained)

Domain interrupted at the frameshift point

  • N-terminal cytoplasmic (intrinsically disordered) — native aa 1–76 retained; aa 77–310 replaced by non-native sequence

Native domains downstream of the frameshift (lost or non-native)

  • Transmembrane helix 1 (aa 311–331)
  • Cytoplasmic loop 1 (aa 332–340)
  • Transmembrane helix 2 (aa 341–361)
  • Lumenal loop 1 (aa 362–370)
  • Transmembrane helix 3 (aa 371–391)
  • Cytoplasmic loop 2 (aa 392–400)
  • Transmembrane helix 4 (aa 401–421)
  • Lumenal loop 2 (aa 422–431)
  • Transmembrane helix 5 (aa 432–452)
  • Cytoplasmic loop 3 (aa 453–461)
  • Transmembrane helix 6 (aa 462–482)
  • Lumenal loop 3 (aa 483–496)
  • Transmembrane helix 7 (aa 497–517)
  • Cytoplasmic loop 4 (aa 518–532)
  • Transmembrane helix 8 (aa 533–553)
  • Lumenal loop 4 (aa 554–573)
  • Transmembrane helix 9 (aa 574–594)
  • Cytoplasmic loop 5 / pre-lumenal (aa 595–599)
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) (aa 600–890)

Clinical evidence

Inheritance and scope

Pathogenic/Likely pathogenic — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Pathogenic/Likely pathogenic, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Not found in the cached WFS1 ClinVar set (_reference/WFS1_clinvar_variants.csv).


Why this variant matters

The frame breaks early enough that the premature stop is caught by nonsense-mediated decay — the transcript is degraded before any out-of-frame protein accumulates. That makes this, in effect, a clean null allele: the atlas points the therapeutic conversation at gene replacement, and notes that readthrough drugs are a weaker fit here than for true nonsense variants because reading through the stop still yields scrambled protein.


Card generated by wolfram-atlas-batch skill (v2 — frameshift pipeline) on 2026-06-08T02:16:27.276478Z. NMD rule and schema definitions: reference/nmd_rules.md, reference/card_schema_extension.md. CDS reference: NM_006005.3 (171..2843). WFS1 reference: UniProt O76024, AlphaFold model v6.